Interleukin 6 and Interleukin 10 in Patients Before and After Lung Transplantation. 2020

Anita Stanjek-Cichoracka, and Elżbieta Woźniak-Grygiel, and Anna Łaszewska, and Tomasz Stącel, and Krzysztof Perć, and Marian Zembala, and Marek Ochman
Department of Biophysics, School of Pharmacy, Division of Laboratory Medicine, Medical University of Silesia in Katowice, Sosnowiec, Poland; Laboratory of Transplant Immunology, Silesian Centre for Heart Diseases, Zabrze, Poland. Electronic address: anita.stanjek@sum.edu.pl.

The aim of the study was to investigate the serum concentration of cytokines (interleukin 6 [IL-6] and IL-10) in patients before and after lung transplantation (LTx). The studied groups consisted of 14 patients (9 men and 5 women aged 47.7 ± 11.4; body mass index [BMI] 21.9 ± 2.3) followed for up to 6 months after LTx and 29 patients (15 men and 14 women, age 49.2 ± 9.4; BMI 23.1 ± 3.7) who were considered for LTx. The study population consisted of patients with idiopathic lung disease (ILD; 8 vs 17) and patients with chronic obstructive pulmonary disease (COPD; 6 vs 12). Cytokine serum levels were assessed using commercially available enzyme-linked immunosorbent assay kits. Significantly lower levels of IL-10 were observed in the group of patients considered for LTx compared to those in recipients (1.8 ± 0.99 vs 5.1 ± 1.44; P = .000726). Significantly lower levels of IL-10 were observed in the group of patients with ILD considered for LTx compared to recipients (1.8 ± 0.95 vs 3.4 ± 1.16; P = .005984). There were no differences in levels of IL-10 in the group of patients with COPD. There were no differences in levels of IL-6 when the studied groups were compared. The present results introduce the cytokines IL-6 and IL-10 in patients before and after LTx. The procedure of LTx influenced increasing of plasma concentration of IL-10. Immunosuppressive drugs may affect IL-10 serum levels. Further studies are needed to evaluate whether analyzed cytokines could be used as biomarkers of clinical status in patients before and after LTx.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D015850 Interleukin-6 A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS. Hepatocyte-Stimulating Factor,Hybridoma Growth Factor,IL-6,MGI-2,Myeloid Differentiation-Inducing Protein,Plasmacytoma Growth Factor,B Cell Stimulatory Factor-2,B-Cell Differentiation Factor,B-Cell Differentiation Factor-2,B-Cell Stimulatory Factor 2,B-Cell Stimulatory Factor-2,BSF-2,Differentiation Factor, B-Cell,Differentiation Factor-2, B-Cell,IFN-beta 2,IL6,Interferon beta-2,B Cell Differentiation Factor,B Cell Differentiation Factor 2,B Cell Stimulatory Factor 2,Differentiation Factor 2, B Cell,Differentiation Factor, B Cell,Differentiation-Inducing Protein, Myeloid,Growth Factor, Hybridoma,Growth Factor, Plasmacytoma,Hepatocyte Stimulating Factor,Interferon beta 2,Interleukin 6,Myeloid Differentiation Inducing Protein,beta-2, Interferon
D016040 Lung Transplantation The transference of either one or both of the lungs from one human or animal to another. Grafting, Lung,Transplantation, Lung,Graftings, Lung,Lung Grafting,Lung Graftings,Lung Transplantations,Transplantations, Lung

Related Publications

Anita Stanjek-Cichoracka, and Elżbieta Woźniak-Grygiel, and Anna Łaszewska, and Tomasz Stącel, and Krzysztof Perć, and Marian Zembala, and Marek Ochman
January 1996, Neoplasma,
Anita Stanjek-Cichoracka, and Elżbieta Woźniak-Grygiel, and Anna Łaszewska, and Tomasz Stącel, and Krzysztof Perć, and Marian Zembala, and Marek Ochman
January 2015, Respiration; international review of thoracic diseases,
Anita Stanjek-Cichoracka, and Elżbieta Woźniak-Grygiel, and Anna Łaszewska, and Tomasz Stącel, and Krzysztof Perć, and Marian Zembala, and Marek Ochman
June 2003, Transplantation proceedings,
Anita Stanjek-Cichoracka, and Elżbieta Woźniak-Grygiel, and Anna Łaszewska, and Tomasz Stącel, and Krzysztof Perć, and Marian Zembala, and Marek Ochman
January 2009, Clinical transplantation,
Anita Stanjek-Cichoracka, and Elżbieta Woźniak-Grygiel, and Anna Łaszewska, and Tomasz Stącel, and Krzysztof Perć, and Marian Zembala, and Marek Ochman
April 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research,
Anita Stanjek-Cichoracka, and Elżbieta Woźniak-Grygiel, and Anna Łaszewska, and Tomasz Stącel, and Krzysztof Perć, and Marian Zembala, and Marek Ochman
May 2002, Transplant immunology,
Anita Stanjek-Cichoracka, and Elżbieta Woźniak-Grygiel, and Anna Łaszewska, and Tomasz Stącel, and Krzysztof Perć, and Marian Zembala, and Marek Ochman
January 1993, Wiener klinische Wochenschrift,
Anita Stanjek-Cichoracka, and Elżbieta Woźniak-Grygiel, and Anna Łaszewska, and Tomasz Stącel, and Krzysztof Perć, and Marian Zembala, and Marek Ochman
May 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,
Anita Stanjek-Cichoracka, and Elżbieta Woźniak-Grygiel, and Anna Łaszewska, and Tomasz Stącel, and Krzysztof Perć, and Marian Zembala, and Marek Ochman
April 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Anita Stanjek-Cichoracka, and Elżbieta Woźniak-Grygiel, and Anna Łaszewska, and Tomasz Stącel, and Krzysztof Perć, and Marian Zembala, and Marek Ochman
March 1994, Critical care medicine,
Copied contents to your clipboard!